Despite a wealth of research, pharmaceutical companies have thus far been unsuccessful in their attempts to address cognitive impairment in schizophrenia. This begs the question: are these compounds truly ineffective or has trial methodology itself been a limiting factor in successfully demonstrating the efficacy of these drugs?

In this webinar, Senior Scientist at Cambridge Cognition – Dr Jack Cotter, discusses the use of cognitive screening and stratification in pharmacotherapy trials for cognitive impairment associated with schizophrenia. 

Watch webinar

Get in touch